SCHEMBL214895

SCHEMBL214895

Cc1cc(Cl)ccc1NC(=O)c1c(C(N)=O)ncn1-c1nc2ccccc2[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 9/20 0.41
TP53 P04637 1/20 0.41
ALDH1A1 P00352 5/20 0.40
HPGD P15428 4/20 0.40
KDM4E B2RXH2 3/20 0.40
STK33 Q9BYT3 1/20 0.39
RAB9A P51151 6/20 0.39
NPC1 O15118 5/20 0.39
TDP1 Q9NUW8 5/20 0.39
POLB P06746 1/20 0.39
KLF5 Q13887 1/20 0.39
THRB P10828 1/20 0.38
MEN1 O00255 4/20 0.38
KMT2A Q03164 4/20 0.38
AURKA O14965 1/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
HTT P42858 3/20 0.38
NPSR1 Q6W5P4 3/20 0.38
CYP1A2 P05177 1/20 0.38
GLA P06280 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL214938 0.88 MAPT (0.47) MAPTTP53ALDH1A1HPGDKDM4E
SCHEMBL213455 0.85 EGLN1 (0.42) MAPTALDH1A1KDM4ESTK33RAB9A
SCHEMBL215084 0.85 MAPT (0.43) MAPTALDH1A1HPGDKDM4ESTK33
SCHEMBL217226 0.84 MEN1 (0.48) MAPTTP53ALDH1A1HPGDKDM4E
SCHEMBL215203 0.84 STK33 (0.40) MAPTALDH1A1STK33RAB9ANPC1
SCHEMBL214963 0.83 LMNA (0.41) MAPTTP53RAB9ANPC1KMT2A
SCHEMBL213365 0.83 TP53 (0.52) MAPTTP53ALDH1A1HPGDKDM4E
SCHEMBL213393 0.83 MAPT (0.46) MAPTALDH1A1HPGDKDM4ESTK33
SCHEMBL216808 0.83 TP53 (0.42) MAPTTP53ALDH1A1HPGDKDM4E
SCHEMBL214714 0.83 MAPT (0.44) MAPTTP53ALDH1A1KDM4ERAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US claimed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US claimed
US-8088767-B2 JAK-2 modulators and methods of use EXELIXIS, INC. (US) 2012-01-03 US disclosed
US-20100136136-A1 JAK-2 Modulators and Methods of Use EXELIXIS, INC. (US) 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100136136-A1 JAK-2 Modulators and Methods of Use JAK2, JAK1, JAK3 MAPT 2138/4885TP53 1743/4885ALDH1A1 4295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.